TVRD

Tvardi Therapeutics, Inc. NASDAQ Listed Apr 16, 2025

Healthcare ·Biotechnology ·US · tvarditherapeutics.com BioSpace +4

$4.21

Mkt Cap $39.5M

52w Low $2.75 3.6% of range 52w High $43.65

50d MA $3.43 200d MA $11.90

P/E (TTM) -1.3x

EV/EBITDA -0.4x

P/B 1.1x

Debt/Equity 0.0x

ROE -87.0%

P/FCF -1.4x

RSI (14) —

ATR (14) —

Beta 0.15

50d MA $3.43

200d MA $11.90

Avg Volume 50.7K

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

SIC Code

2834

CIK (SEC)

1346830

Phone

832-413-1362

2450 Holcombe Blvd, Suite X · Sugar Land, TX 77021 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-0.55	-0.78	-41.8%	3.18	-1.6%	-5.7%	+0.7%	-1.3%	-4.4%	+7.0%	—
Nov 13, 2025	AMC	-0.83	-0.59	+28.9%	4.11	-0.7%	-1.9%	+0.0%	+2.2%	-4.6%	-2.8%	—
Aug 14, 2025	AMC	-0.51	-1.00	-96.1%	23.79	+3.4%	+0.9%	+3.1%	-0.3%	+9.0%	-0.9%	—
May 13, 2025	AMC	-0.58	-3.22	-450.4%	26.54	-4.4%	-0.7%	+1.6%	-5.8%	+3.8%	+5.9%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	Barclays	Downgrade	Equal Weight → Underweight	—	$3.39	$3.38	-0.3%	-5.0%	-1.9%	+2.2%	-6.8%	+3.0%
Apr 1	Barclays	Maintains	Equal Weight → Equal Weight	—	$3.18	$3.13	-1.6%	-5.7%	+0.7%	-1.3%	-4.4%	+7.0%
Apr 1	BTIG	Maintains	Buy → Buy	—	$3.18	$3.13	-1.6%	-5.7%	+0.7%	-1.3%	-4.4%	+7.0%
Apr 1	Piper Sandler	Maintains	Neutral → Neutral	—	$3.18	$3.13	-1.6%	-5.7%	+0.7%	-1.3%	-4.4%	+7.0%
Oct 14	Raymond James	Downgrade	Outperform → Market Perform	—	$6.69	$6.65	-0.6%	+4.6%	-5.1%	-2.4%	+1.5%	-6.2%
Oct 13	BTIG	Maintains	Buy → Buy	—	$41.60	$6.20	-85.1%	-83.9%	+4.6%	-5.1%	-2.4%	+1.5%

Data updated apr 27, 2026 6:08am · Source: massive.com